Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Biocon Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

19 Apr 2014 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - BIOCON LIMITED (BIOCON-IN)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

24 Apr 2014 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for Biocon Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

09 Apr 2014 Wright Reports 41 $75.00

Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review

Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review Summary Biocon Limited (Biocon) is a biotechnology com...

04 Apr 2014 GlobalData 47 $125.00

Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review

Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review Summary Biocon Limited (Biocon) is a biotechnology com...

05 Feb 2014 GlobalData 47 $125.00

Biocon keeps sliding: down 11.8% in 3 days

Biocon Limited (NSE:BIOCON), India's 14th largest pharmaceuticals company by market capitalisation, extended its slide Friday...

24 Jan 2014 News Bites Pty Limited 18 $5.00

MOSL: BIOCON (Neutral) - Muted quarter due to abrupt slowdown in biopharma

Biocon (BIOS IN, Mkt Cap USD1.5b, CMP INR452, Neutral) Alok Dalal (Alok.Dalal@MotilalOswal.com) / Hardick Bora (Hardick.Bora...

24 Jan 2014 Motilal Oswal Securities Ltd. 8 $81.00

Spark Capital: Biocon – Q3 FY14 results review – Weak quarter, execution on insulin facility in Malaysia and global phase III glargine trials will be key; maintain ‘Add’

Weak quarter, execution on insulin facility in Malaysia and global phase III glargine trials will be key; maintain ‘Add’ Bio...

24 Jan 2014 Spark Capital Advisors(India) Private Limited 6 $35.00

Biocon Ltd. (BIOS) - Qtr. Update - Dated - January 23, 2014

Raise target PE on better growth visibility but downgrade to HOLD on stock price appreciation Biocon’s (Bloomberg: BIOS IN) ...

24 Jan 2014 Axis Capital Limited 4 $35.00

Biocon Ltd. | Q3FY14 Result Update | Street counting R&D chickens too early,

Biocon Ltd. | Q3FY14 Result Update Street counting R&D chickens too early, though we remain cautious, maintain HOLD with the...

23 Jan 2014 IndiaNivesh Securities Pvt Ltd 4 $35.00